8-K Announcements
6Material company update
May 11, 2026·SEC
Material company update
Apr 28, 2026·SEC
Material company update
Mar 24, 2026·SEC
Biomea Fusion, Inc.(BMEA)Earnings, Financials & Key Ratios
BMEA•NASDAQ
$1.40
Price updated Jul 7, 2026
AboutBiomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in oncogenic signaling in multiple cancers. The company was incorporated in 2017 and is headquartered in Redwood City, California.Show more
- Revenue$0
- EBITDA-$80M+43.9%
- Net Income-$62M+55.4%
- EPS (Diluted)-1.18+69.2%
- ROE-152.35%-21.5%
BMEA Price & Volume
Biomea Fusion, Inc. (BMEA) stock price & volume — 10-year historical chart
Loading chart...
Persistent Clinical Burn Threatens Capital Runway Stability
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Clinical trial funding dependency
Key Thesis Takeaways
- Biomea Fusion faces a precarious financial outlook as it continues to fund its proprietary FUSION platform through aggressive R&D spending without generating commercial revenue.
- While the company has moderated R&D expenses from $33.8 million in 2024Q1 to $9.1 million in 2026Q1, the lack of a sustainable path to profitability remains a primary concern for investors.
- The firm's reliance on external financing is underscored by a significant erosion of total assets, which fell from $199.9 million in 2023Q4 to $46.4 million in 2026Q1, necessitating careful monitoring of future capital raises.
Verdict Logic
the company's cash position of $44.7 million against a history of quarterly operating losses exceeding $10 million suggests a high probability of dilutive financing requirements in the near term.
BMEA Growth Metrics
Biomea Fusion, Inc. (BMEA) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-
3 Years-
TTM-
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM65.05%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM75.04%
Return on Capital
10 Years-78.9%
5 Years-91.18%
3 Years-121.35%
Last Year-153.79%
BMEA Recent Earnings
Biomea Fusion, Inc. (BMEA) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 7/12 qtrs (58%)
Q2 2026Latest
May 11, 2026Metric
Actual
Est
EPS
$0.17+29.2%
$0.24
Rev
—
—
Q2 2026
Mar 24, 2026Metric
Actual
Est
EPS
$0.64-156.0%
$0.25
Rev
—
—
Q4 2025
Nov 4, 2025Metric
Actual
Est
EPS
$0.27-3.8%
$0.26
Rev
—
—
Q3 2025
Aug 5, 2025Metric
Actual
Est
EPS
$0.51+13.6%
$0.59
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.17vs $0.24+29.2% | — |
| Q2 2026 | Mar 24, 2026 | $0.64vs $0.25-156.0% | — |
| Q4 2025 | Nov 4, 2025 | $0.27vs $0.26-3.8% | — |
| Q3 2025 | Aug 5, 2025 | $0.51vs $0.59+13.6% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Biomea Fusion, Inc. (BMEA)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $1.40 | $83.29M | -1.19 | — | — | -152.35% | — | |
| $119.24 | $9.74B | -32.31 | -16.72% | -612.17% | -25.02% | — | |
| $8.59 | $554.24M | -6.71 | -0.3% | -247.54% | -44.39% | — | |
| $0.67 | $28.65M | -1.08 | 13.77% | -4726.21% | -69.57% | — | |
| $40.09 | $8.23B | -14.47 | — | — | -68.16% | — | |
| $323.95 | $9.36B | -24.03 | -100% | — | -43.02% | — |
Compare BMEA vs Peers
Biomea Fusion, Inc. (BMEA) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
BMEA SEC Filings & Documents
Biomea Fusion, Inc. (BMEA) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when BMEA posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
BMEA Frequently Asked Questions
Biomea Fusion, Inc. (BMEA) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
Is BMEA profitable?
Biomea Fusion, Inc. (BMEA) reported a net loss of $45.0M for fiscal year 2025.
Dividend & Returns
What is BMEA's return on equity?
Biomea Fusion, Inc. (BMEA) has a return on equity (ROE) of -152.4%. Negative ROE indicates the company is unprofitable.
What is Biomea Fusion, Inc.'s free cash flow?
Biomea Fusion, Inc. (BMEA) had negative free cash flow of $56.2M in fiscal year 2025, likely due to heavy capital investments.